Based on these studies, third-generation EGFR-TKIs show superior efficacy and safety in patients with brain/meningeal metastases from EGFR-mutated NSCLC, and dose escalation may be a better treatment strategy. Here, EGFR is linked to non-small cell lung carcinoma.